Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Plasma cells help you fight infections by making antibodies that recognize and attack germs.
Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. Rather than produce helpful antibodies, the cancer cells produce abnormal proteins that can cause complications.
Treatment for multiple myeloma isn't always necessary for people who aren't experiencing any signs or symptoms. For people with multiple myeloma who require treatment, a number of treatments are available to help control the disease.
Multiple myeloma care at Mayo Clinic
Source: http://www.mayoclinic.com
Signs and symptoms of multiple myeloma can vary and, early in the disease, there may be none.
When signs and symptoms do occur, they can include:
Make an appointment with your doctor if you have any persistent signs and symptoms that worry you.
Source: http://www.mayoclinic.com
It's not clear what causes myeloma.
Doctors know that myeloma begins with one abnormal plasma cell in your bone marrow â the soft, blood-producing tissue that fills in the center of most of your bones. The abnormal cell multiplies rapidly.
Because cancer cells don't mature and then die as normal cells do, they accumulate, eventually overwhelming the production of healthy cells. In the bone marrow, myeloma cells crowd out healthy white blood cells and red blood cells, leading to fatigue and an inability to fight infections.
The myeloma cells continue trying to produce antibodies, as healthy plasma cells do, but the myeloma cells produce abnormal antibodies that the body can't use. Instead, the abnormal antibodies (monoclonal proteins, or M proteins) build up in the body and cause problems such as damage to the kidneys. Cancer cells can also cause damage to the bones that increases the risk of broken bones.
Multiple myeloma almost always starts out as a relatively benign condition called monoclonal gammopathy of undetermined significance (MGUS).
In the United States, about 3 percent of people older than age 50 have MGUS. Each year, about 1 percent of people with MGUS develop multiple myeloma or a related cancer.
MGUS, like multiple myeloma, is marked by the presence of M proteins â produced by abnormal plasma cells â in your blood. However, in MGUS, the levels of M proteins are lower and no damage to the body occurs.
Source: http://www.mayoclinic.com
In some cases, your doctor may detect multiple myeloma accidentally when you undergo a blood test for some other condition. In other cases, your doctor may suspect multiple myeloma based on your signs and symptoms.
Tests and procedures used to diagnose multiple myeloma include:
Blood tests. Laboratory analysis of your blood may reveal the M proteins produced by myeloma cells. Another abnormal protein produced by myeloma cells â called beta-2-microglobulin â may be detected in your blood and give your doctor clues about the aggressiveness of your myeloma.
Additionally, blood tests to examine your kidney function, blood cell counts, calcium levels and uric acid levels can give your doctor clues about your diagnosis.
Examination of your bone marrow. Your doctor may remove a sample of bone marrow for laboratory testing. The sample is collected with a long needle inserted into a bone (bone marrow aspiration and biopsy).
In the lab, the sample is examined for myeloma cells. Specialized tests, such as fluorescence in situ hybridization (FISH) can analyze myeloma cells to understand their genetic abnormalities. Tests are also done to measure the rate at which the myeloma cells are dividing.
If tests indicate you have multiple myeloma, your doctor will use the information gathered from the diagnostic tests to classify your disease as stage I, stage II or stage III. Stage I indicates a less aggressive disease, and stage III indicates an aggressive disease that may affect bone, kidneys and other organs.
Your multiple myeloma may also be assigned a risk category, which indicates the aggressiveness of your disease.
Your multiple myeloma stage and risk category help your doctor understand your prognosis and your treatment options.
Source: http://www.mayoclinic.com
Complications of multiple myeloma include:
Source: http://www.mayoclinic.com
No alternative medicines have been found to treat multiple myeloma. But alternative medicine may help you cope with the stress and side effects of myeloma and myeloma treatment.
Talk to your doctor about your options, such as:
Talk with your doctor before trying any of these techniques to make sure they don't pose any risks for you.
Source: http://www.mayoclinic.com
A cancer diagnosis can be shocking and devastating. With time, you'll find ways to cope with the stress and uncertainty of living with cancer. Until you find what works best for you, consider trying to:
Learn enough to make decisions about your care. Learn enough about multiple myeloma so that you're able to participate in decisions about your treatment and care. Ask your doctor about your treatment options and their side effects.
You may find additional help gathering information through your local library and online. Start with the National Cancer Institute and the International Myeloma Foundation.
Maintain a strong support system. Having a strong support system can help you cope with issues and anxieties that might occur. Your friends and family may be willing to offer support.
You might also find that support from a formal support group or others coping with cancer may be helpful. Friends you meet in support groups may be willing to share practical advice for coping with cancer and cancer treatment. Support groups are also available online.
Source: http://www.mayoclinic.com
Factors that may increase your risk of multiple myeloma include:
Source: http://www.mayoclinic.com
We respect your privacy and aim for the best website experience in compliance with local laws. Allowing cookies enables a tailored experience, while disabling them may reduce personalization. For more information, please read our Privacy Policy and Cookie Policy.